| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/03/2002 | WO2002000602A1 Benzophenones and sulfones as inhibitors of glycine uptake |
| 01/03/2002 | WO2002000593A2 Compounds useful for the preparation of medicaments with phosphodiesterase iv inhibitory activity |
| 01/03/2002 | WO2002000285A1 Method for curing drug dependence |
| 01/03/2002 | WO2002000268A1 Sprayable wound care compositions |
| 01/03/2002 | WO2002000263A2 Tripeptide prodrug compounds |
| 01/03/2002 | WO2002000262A2 Modulation of chromosome function by chromatin remodeling agents |
| 01/03/2002 | WO2002000260A1 Remedial agent for optic nerve disease and the like |
| 01/03/2002 | WO2002000258A1 Medicinal compositions for angiogenic therapy |
| 01/03/2002 | WO2002000257A1 Remedies for alzheimer's disease |
| 01/03/2002 | WO2002000256A1 Remedies for cirrhosis |
| 01/03/2002 | WO2002000255A1 Remedies for cancer |
| 01/03/2002 | WO2002000250A2 Hiv-1 vaccines and screening methods therefor |
| 01/03/2002 | WO2002000244A2 Protein mixtures for wound healing |
| 01/03/2002 | WO2002000240A2 Compositions and methods for treating females sexual response |
| 01/03/2002 | WO2002000239A1 Antiallergic agents, drugs, foods, drinks or cosmetics containing them and process for producing the same |
| 01/03/2002 | WO2002000228A1 Oxygen-containing ophthalmic composition |
| 01/03/2002 | WO2002000227A2 Use of lanthanum compounds for the treatment of bone diseases |
| 01/03/2002 | WO2002000226A1 A synthetic bulk laxative |
| 01/03/2002 | WO2002000225A1 7-hydroxyepiandrosterone having neuroprotective activity |
| 01/03/2002 | WO2002000224A1 Neuroprotective 7-beta-hydroxysteroids |
| 01/03/2002 | WO2002000223A1 Use of potassium channel agonists for reducing fat food comsumption |
| 01/03/2002 | WO2002000222A1 Use of potassium channel agonists for the treatment of cancer |
| 01/03/2002 | WO2002000221A1 Enhanced brain function by gaba-ergic stimulation |
| 01/03/2002 | WO2002000220A1 A method for treating septic shock |
| 01/03/2002 | WO2002000219A1 Sustained-release preparations of quinolone antibiotics and method for preparation thereof |
| 01/03/2002 | WO2002000218A2 Methods of treating neutrophil-related diseases with topical anesthetics |
| 01/03/2002 | WO2002000217A1 Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators |
| 01/03/2002 | WO2002000216A1 Carvedilol |
| 01/03/2002 | WO2002000215A1 Subtype selective melatonergics |
| 01/03/2002 | WO2002000214A1 Flavone/flavanone derivatives for the systemic treatment and prophylaxis of uv-induced dermatoses |
| 01/03/2002 | WO2002000213A1 Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
| 01/03/2002 | WO2002000212A1 Controlled release arginine formulations |
| 01/03/2002 | WO2002000211A1 Use of fluorocarbons for the prevention of surgical adhesions |
| 01/03/2002 | WO2002000210A2 Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease |
| 01/03/2002 | WO2002000209A2 Gabapentin analogues for sleep disorders |
| 01/03/2002 | WO2002000204A1 Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates |
| 01/03/2002 | WO2002000203A1 Topical pharmaceutical formulations and methods of treatment |
| 01/03/2002 | WO2002000201A2 Method for preparing a composition |
| 01/03/2002 | WO2002000200A1 Novel process for preparing crystalline particles |
| 01/03/2002 | WO2002000199A1 Novel process for preparing and harvesting crystalline particles |
| 01/03/2002 | WO2002000198A1 Process for preparing and harvesting crystalline particles |
| 01/03/2002 | WO2002000197A1 Method of making particles for use in a pharmaceutical composition |
| 01/03/2002 | WO2002000196A2 Wet milling process |
| 01/03/2002 | WO2002000195A2 Methods and compositions for treating pain of the mucous membrane |
| 01/03/2002 | WO2002000194A2 Polymeric micelle compositions |
| 01/03/2002 | WO2002000188A1 Use of inulin and inulin derivatives |
| 01/03/2002 | WO2002000187A1 Use of inulins and inulin derivatives |
| 01/03/2002 | WO2002000183A2 Use of egf-r protein tyrosine kinase inhibitors for preventing photoaging in human skin |
| 01/03/2002 | WO2002000175A2 Enhancing therapeutic effectiveness of nitric oxide inhalation |
| 01/03/2002 | WO2002000174A2 Compositions and methods for the therapy and diagnosis of lung cancer |
| 01/03/2002 | WO2002000170A2 Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer |
| 01/03/2002 | WO2002000168A2 Combination hiv therapy including camptothecin |
| 01/03/2002 | WO2002000167A2 Modified forms of pharmacologically active agents and uses therefor |
| 01/03/2002 | WO2002000166A2 New compounds useful as antibacterial agents |
| 01/03/2002 | WO2002000165A2 Agent for reversal of drug resistance in mycobacterium tuberculosis |
| 01/03/2002 | WO2002000164A2 Chemosensitizer |
| 01/03/2002 | WO2002000163A2 The method of treating drug resistant mycobacterium tuberculosis infection |
| 01/03/2002 | WO2002000161A1 Medicinal product package for eradication therapy |
| 01/03/2002 | WO2002000137A1 Biodegradable vehicles and delivery systems of biologically active substances |
| 01/03/2002 | WO2002000042A2 Compositions and methods for body weight management |
| 01/03/2002 | WO2002000024A1 New strategy for leukemia therapy |
| 01/03/2002 | WO2002000017A2 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of erk-5 |
| 01/03/2002 | WO2001072669A3 Therapeutic use of polyhydroxy amine derivates |
| 01/03/2002 | WO2001071005A3 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| 01/03/2002 | WO2001070744A3 Process for the preparation of midazolam |
| 01/03/2002 | WO2001070693A3 Difluorobutyric acid derivatives and their use as metalloprotease inhibitors |
| 01/03/2002 | WO2001066544A3 Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers |
| 01/03/2002 | WO2001064187A3 Anaesthetic formulations |
| 01/03/2002 | WO2001062233A3 Adenosine receptor modulators |
| 01/03/2002 | WO2001055336A3 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 01/03/2002 | WO2001053344A3 Chondromodulin-i related peptide |
| 01/03/2002 | WO2001051473A8 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation |
| 01/03/2002 | WO2001051083A3 Innate immunity-stimulating compositions of cpg and saponin and methods thereof |
| 01/03/2002 | WO2001049713A3 Stabilizing peptides, polypeptides and antibodies which include them |
| 01/03/2002 | WO2001045695A3 Calcium formate for use as a phosphorus binder and a dietary supplement |
| 01/03/2002 | WO2001045689A3 Indolinone derivatives for modulation of c-kit tyrosine protein kinase |
| 01/03/2002 | WO2001045676A3 Extended release oral dosage composition |
| 01/03/2002 | WO2001044260A3 Novel purines |
| 01/03/2002 | WO2001043749A3 Pharmaceutical implant containing immediate-release and sustained-release components and method of administration |
| 01/03/2002 | WO2001043748A3 Implant composition containing melengestrol acetate and trenbolone acetate |
| 01/03/2002 | WO2001043734A3 Transdermal administration of phenylpropanolamine |
| 01/03/2002 | WO2001042265A3 N6 heterocyclic 8-modified adenosine derivatives |
| 01/03/2002 | WO2001039757A3 Surfactants as malarial chloroquine resistance reversal agents |
| 01/03/2002 | WO2001035935A3 Inhibitors of endo-exonuclease activity such as pentamidine for the treatment of cancer |
| 01/03/2002 | WO2001028587A3 Magnetic targeted carrier |
| 01/03/2002 | WO2001028532A3 Methods and compositions for predicting, diagnosing and treating lipodystrophy |
| 01/03/2002 | WO2001028527A3 Direct compression polymer tablet core |
| 01/03/2002 | WO2001024826A3 Inrease of enos activity through activation of the pi3-kinase/akt pathway by estrogens |
| 01/03/2002 | WO2001015697A8 Use of at least one substance based on nicotine and/or a substance produced from said one substance for the manufacture of a medicament, and a method for treatment of obstructive lung diseases |
| 01/03/2002 | WO2001015678A3 Topical use of kappa opioid agonists to treat otic pain |
| 01/03/2002 | WO2000071563A3 Taccalonolide microtubule stabilizing agents |
| 01/03/2002 | WO2000061549A3 Pharmaceutical compounds |
| 01/03/2002 | WO2000061171A9 Uses of mammalian ox2 protein and related reagents |
| 01/03/2002 | WO2000061146A9 Camptothecin analogs and methods of preparation thereof |
| 01/03/2002 | US20020002353 Therapeutic, diagnostic, or hydrophilic coating for an intracorporeal medical device |
| 01/03/2002 | US20020002296 Cytoprotective Compounds |
| 01/03/2002 | US20020002283 Process for preparing growth hormone secretagogues |
| 01/03/2002 | US20020002282 Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate |
| 01/03/2002 | US20020002279 Heat resistance; storage stability |
| 01/03/2002 | US20020002272 Eliciting HCV-specific antibodies |